Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Johan Ahlgren(Gävle Hospital), Carl Blomqvist(University of Helsinki), Peter Nygren(Uppsala University), Gunnar Åström(Uppsala University), Kenneth Villman(Örebro University Hospital)
Acta Oncologica
October 2, 2006
10.1080/02841860600871087
Cited by 8

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k